Showing 1,201 - 1,220 results of 3,675 for search '(( significant decrease decrease ) OR ( significantly lower decrease ))~', query time: 0.43s Refine Results
  1. 1201

    O<sub>2</sub> concentration under different conditions. by Zihao Chai (20521844)

    Published 2025
    “…Regarding the oxygen consumption activation energy, the primary oxidation process exhibited lower values in the first and second stages, but in the third stage, the secondary oxidation process at 25 mL/min and 100 mL/min air flow had lower oxygen consumption activation energy, while at 50 mL/min and 200 mL/min air flow, the primary oxidation process had lower oxygen consumption activation energy. …”
  2. 1202
  3. 1203

    Study data. by Jie Liu (15128)

    Published 2025
    “…The drug cost of the roxadustat group was higher, but another additional cost for correcting anemia was significantly reduced. The infection rate of COVID-19 and the mortality rate caused by COVID-19 were lower in roxadustat group.…”
  4. 1204

    Summary of clinical outcomes after 9 months. by Jie Liu (15128)

    Published 2025
    “…The drug cost of the roxadustat group was higher, but another additional cost for correcting anemia was significantly reduced. The infection rate of COVID-19 and the mortality rate caused by COVID-19 were lower in roxadustat group.…”
  5. 1205

    Approval by the research ethics committee. by Jie Liu (15128)

    Published 2025
    “…The drug cost of the roxadustat group was higher, but another additional cost for correcting anemia was significantly reduced. The infection rate of COVID-19 and the mortality rate caused by COVID-19 were lower in roxadustat group.…”
  6. 1206
  7. 1207
  8. 1208
  9. 1209
  10. 1210
  11. 1211

    Baseline characteristics. by Daniela Sánchez-Santiesteban (21192342)

    Published 2025
    “…In Colombia, despite a healthcare system covering 97% of the population, socioeconomic disparities persist. Lower income levels are associated with decreased survival, potentially due to delays in diagnosis or treatment and a higher probability of advanced staging at diagnosis, These inequities persist even among relatively advantaged populations, such as formal employee who are assumed to have fewer barriers to accessing healthcare services compared to informal workers.…”
  12. 1212

    Baseline characteristics of participants. by Hyungjong Park (10147327)

    Published 2025
    “…</p><p>Conclusions</p><p>The general population with RHF may have a lower risk of incidence of dyslipidemia. The identified inverse association between RHF and dyslipidemia underscores its significance in risk stratification and preventive interventions in clinical practice.…”
  13. 1213
  14. 1214

    PRISMA flow diagram of study selection. by Masoud Rahmati (16665456)

    Published 2025
    “…In contrast, distance vision impairment showed lower but still significant associations with IADL (OR = 1.19, 95% CI 1.05–1.34, <i>p</i> = 0.005) and a nonsignificant association with ADL (OR = 1.12, 95% CI 0.90–1.40, <i>p</i> = 0.30). …”
  15. 1215

    General characteristics of included studies. by Masoud Rahmati (16665456)

    Published 2025
    “…In contrast, distance vision impairment showed lower but still significant associations with IADL (OR = 1.19, 95% CI 1.05–1.34, <i>p</i> = 0.005) and a nonsignificant association with ADL (OR = 1.12, 95% CI 0.90–1.40, <i>p</i> = 0.30). …”
  16. 1216

    Characteristics of individual studies. by Masoud Rahmati (16665456)

    Published 2025
    “…In contrast, distance vision impairment showed lower but still significant associations with IADL (OR = 1.19, 95% CI 1.05–1.34, <i>p</i> = 0.005) and a nonsignificant association with ADL (OR = 1.12, 95% CI 0.90–1.40, <i>p</i> = 0.30). …”
  17. 1217

    Participant flow (CONSORT diagram). by David J. Diemert (8135568)

    Published 2024
    “…Peak anti-<i>Na</i>-GST-1 IgG levels were observed between 2 and 4 weeks following the third dose, regardless of <i>Na</i>-GST-1 formulation. IgG levels decreased but remained significantly above baseline in all groups by day 290, at which point all participants (20 of 20 evaluable participants) still had detectable IgG. …”
  18. 1218
  19. 1219
  20. 1220